ARTICLE | Company News

NICE backs GSK's Tafinlar for melanoma

October 22, 2014 3:53 AM UTC

NICE issued final guidance recommending Tafinlar dabrafenib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to treat unresectable metastatic melanoma with a BRAF V600 mutation, its approved indication.

The committee concluded that the oral BRAF protein kinase inhibitor improved progression-free survival compared to dacarbazine chemotherapy and that its cost-effectiveness is similar to Zelboraf vemurafenib from Roche (SIX:ROG; OTCQX:RHHBY), which NICE recommends to treat unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma. ...